The MOMI-VAX study, a new observational research endeavor launched last month to investigate the immune responses elicited by COVID-19 vaccines administered to a target population, including 750 pregnant women or 250 postpartum women, was announced by the National Institutes of Health in June. In this study, researchers evaluate the development and durability of antibodies in response to SARS-CoV-2, the virus behind COVID-19. According to a Centers for Disease Control and Prevention (CDC) report, 107 pregnant women died with COVID-19 from the period January 22, 2020, through June 21, 2021. In this study, the investigators are also evaluating overall vaccine safety while probing as to the effective transfer of vaccine-induced antibodies to infants across the placenta and via breast milk. Consequently, the study team scrutinizes the breast milk antibodies with the aim of better understanding the possible protections against COVID-19 in breastfed infants.
What follows is a brief TrialSite breakdown of this study.
What is the rationale for studying this cohort population?
According to a recent NIH press release, pregnant people with COVID-19 are more likely to be ho...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).